MTOR and breast carcinoma: To determine the response of these PDX models to an mTOR inhibitor, we treated them with everolimus as single agent, given at 2.5 mg/kg 3/week, a dose well tolerated and highly efficient in PDX models of ER+ breast cancer [13].